Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
Capricor Therapeutics (NASDAQ: CAPR) will announce its financial results for Q1 2021 on May 13, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the financial performance and recent corporate updates. Capricor focuses on cell- and exosome-based therapies, particularly its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy and cytokine storms in COVID-19 patients. The company is also advancing its exosome platform technology for various diseases.
- Upcoming Q1 2021 financial results release scheduled for May 13, 2021.
- Management will conduct a conference call to provide insights into financial performance and corporate updates.
- None.
Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET
LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2021, after the market close on Thursday May 13, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13.
| Title: | Capricor Therapeutics First Quarter 2021 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Thursday, May 13, 2021 |
| Time: | 4:30 p.m. ET |
| Conference Call Details: | Toll-Free: 877-451-6152 |
| International: 201-389-0879 | |
| Conference ID: 13719513 | |
| Webcast: | http://public.viavid.com/index.php?id=144798 |
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics and vaccines for the treatment and prevention of a broad spectrum of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing our exosomes platform technology as a next-generation therapeutic platform. Our current focus is on the development of exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases. For more information, visit www.capricor.com and follow the Company on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 15, 2021. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 212.896.1204
Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
617.435.6602
Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
310.358.3200
FAQ
When will Capricor Therapeutics release its Q1 2021 financial results?
What time is the Capricor Therapeutics conference call?
What is Capricor Therapeutics' lead product candidate?
